Bachem Holding stock trades near its 52-week high as capex rises

Published on 09/24/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem Holding stock posted H1 2026 sales of CHF 326.4 million, up 4.3 percent year over year. EBITDA fell 9.0 percent to CHF 82.8 million as capacity spending accelerated.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem Holding stock (ISIN CH1176493729) closed at CHF 83.35 on the Swiss Exchange on September 23, 2026, just 0.89 percent below its 52-week high of CHF 84.10. The share price slipped 0.18 percent during the session as investors weighed rapid capacity expansion against weaker interim profitability.

Sales rise as margins narrow

According to Börse Express, Bachem reported H1 2026 revenue of CHF 326.4 million, up 4.3 percent from the prior-year period and 7.3 percent in local currencies. EBITDA declined 9.0 percent to CHF 82.8 million, leaving the margin at 25.4 percent.

The comparison explains the market tension: demand is still generating growth, but the cost of bringing new production capacity online is absorbing part of that expansion. The CHF 148.4 million investment in property, plant and equipment during H1 2026 equaled 45.5 percent of reported first-half revenue.

More than CHF 500 million for capacity

Bachem is extending its peptide and oligonucleotide manufacturing network through a large-scale facility at Sisslerfeld in Eiken. Pharma Manufacturing reported on September 24, 2026, that the project involves more than CHF 500 million and is linked to demand for peptide active pharmaceutical ingredients, including GLP-1 medicines.

That investment creates a clear financial tradeoff. The company is committing capital ahead of future commercial volumes, while the H1 margin decline shows that ramp-up expenses are already visible in the income statement. For investors, the key checkpoint is whether additional capacity converts into faster sales growth without keeping EBITDA below the 2025 level.

Stock remains near its yearly peak

The Swiss Exchange price of CHF 83.35 on September 23, 2026, stood above the session open of CHF 83.40 only after a late-day decline and remained close to the 52-week high of CHF 84.10. The daily range was CHF 82.35 to CHF 84.10, with 67,428 shares traded.

Bachem Holding therefore combines a quantified growth signal with a quantified execution cost. Revenue increased 4.3 percent in H1 2026, while EBITDA decreased 9.0 percent, and the CHF 148.4 million capital program now provides the central test for the company valuation.

CHF 83.35 close sets the reference

Bachem Holding stock closed at CHF 83.35 on the Swiss Exchange on September 23, 2026, down 0.18 percent from CHF 83.50. The reference price was 0.89 percent below the 52-week high of CHF 84.10.